DIL Limited subsidiary, Fermenta Biotech Limited wins accolades at UBM India Pharma Awards 2018

~Fermenta Biotech Limited wins Awards for Excellence in Export Promotion, Pharma International Excellence and Excellence in Corporate Social Responsibility~

Mumbai, December 18, 2018: DIL Ltd.(BSE: DIL: 506414) today announced that its subsidiary, Fermenta Biotech Ltd.(FBL) was recognized for excellence at the UBM India Pharma Awards 2018. FBL won three awards including Awards for Excellence in Export Promotion, Pharma International Excellence and Excellence in Corporate Social Responsibility. The prestigious awards were conferred on FBL at a grand event in Delhi attended by pharma industry leaders and visionaries from across the world.

Mr.Prashant Nagre, CEO, Fermenta Biotech Ltd. said, “These awards are testament to our efforts to remain ahead of the curve in a competitive global environment. We are happy to be recognized for our excellence amongst our peers. The award for our CSR efforts is a result of our belief that we should always give back to the community we are present in, and we are happy that our small contribution has been recognized.”

The Excellence in Export Promotion Award was given to FBL for its steady growth in exports over the years with an over 100% growth in FY18 over the previous year. A growth in export customers from 106 in FY15 to 171 in FY18 is a demonstration of its increasing global footprint across 50+ countries over six continents. The world class manufacturing facilities of FBL are cleared by most of the global regulatory agencies including US-FDA and WHO-GMP, and FBL has today established India as a credible alternative to China in the vitamin segment.